GLP-1 Brand Comparison

Mounjaro vs Zepbound: What's the Difference?

Verdict Summary

Mounjaro and Zepbound both contain Tirzepatide. Mounjaro is approved for Type 2 diabetes; Zepbound for obesity. The active ingredient is identical.

Medical Disclaimer: This comparison is for educational purposes only. Consult a healthcare provider before starting any peptide protocol. Full disclaimer →

At a Glance

DimensionMounjaroZepbound
Active IngredientTirzepatideTirzepatide
FDA IndicationType 2 diabetesChronic weight management
Maximum Dose15 mg/week15 mg/week
ManufacturerEli LillyEli Lilly
Average Weight Loss~15–20%~15–22.5%

Mounjaro Deep Dive

Mounjaro (Tirzepatide) is FDA-approved for Type 2 diabetes management. It produces superior glycemic control compared to GLP-1 monotherapy due to its dual GIP/GLP-1 mechanism, and significant weight loss as a secondary benefit.

Zepbound Deep Dive

Zepbound (Tirzepatide) is FDA-approved for chronic weight management. It uses the same molecule as Mounjaro at the same doses, with FDA approval specifically for the obesity indication.

How to Choose

Choose Mounjaro if…

  • You have Type 2 diabetes as the primary indication
  • Your insurance covers Mounjaro for diabetes

Choose Zepbound if…

  • Weight loss is your primary goal without a diabetes diagnosis
  • Your insurance covers Zepbound for obesity

Consider Both If…

The active ingredient is identical — the choice is driven entirely by your diagnosis and insurance coverage.

Still Unsure?

Get a personalized recommendation

Take the 5-minute PeptidePilot quiz. Our algorithm evaluates your goals, body, and lifestyle to recommend the right peptide for you — vendor-neutral.

Frequently Asked Questions

More Comparisons